BRPI0508461B8 - diaminopirimidinas, seus usos, e composição farmacêutica - Google Patents

diaminopirimidinas, seus usos, e composição farmacêutica

Info

Publication number
BRPI0508461B8
BRPI0508461B8 BRPI0508461A BRPI0508461A BRPI0508461B8 BR PI0508461 B8 BRPI0508461 B8 BR PI0508461B8 BR PI0508461 A BRPI0508461 A BR PI0508461A BR PI0508461 A BRPI0508461 A BR PI0508461A BR PI0508461 B8 BRPI0508461 B8 BR PI0508461B8
Authority
BR
Brazil
Prior art keywords
diaminopyrimidines
pharmaceutical composition
methods
prodrug
solvate
Prior art date
Application number
BRPI0508461A
Other languages
English (en)
Inventor
Jahangir Alam
Allen Broka Chris
Jeou Jen Lin Clara
Warren Parish Daniel
Scott Carter David
Patrick Dillon Michael
Charles Hawley Ronald
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to BR122018003623A priority Critical patent/BR122018003623B8/pt
Publication of BRPI0508461A publication Critical patent/BRPI0508461A/pt
Publication of BRPI0508461B1 publication Critical patent/BRPI0508461B1/pt
Publication of BRPI0508461B8 publication Critical patent/BRPI0508461B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • C07D239/49Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

diaminopirimidinas como antagonistas de p2x3 e p2x2/3 compostos e métodos para tratar doenças mediadas por um antagonista de receptor p2x~ 3~ e/ou um p2x~ 2~/3~, os métodos compreendendo a administração a um indivíduo em necessidade do mesmo de uma quantidade eficaz de um composto da fórmula (i) ou um sal farmaceuticamente aceitável, solvato ou prodroga do mesmo, em que d, x, y, r^ 1^, r^ 2^ , r^ 3^ , r^ 4^, r^ 5^, r^ 6^, r^ 7^ e r^ 8^ são como definidos aqui.
BRPI0508461A 2004-03-05 2005-02-25 diaminopirimidinas, seus usos, e composição farmacêutica BRPI0508461B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122018003623A BR122018003623B8 (pt) 2004-03-05 2005-02-25 diaminopirimidinas, seus usos, e composição farmacêutica

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55049904P 2004-03-05 2004-03-05
US60/550,499 2004-03-05
PCT/EP2005/002020 WO2005095359A1 (en) 2004-03-05 2005-02-25 Diaminopyrimidines as p2x3 and p2x2/3 antagonists

Publications (3)

Publication Number Publication Date
BRPI0508461A BRPI0508461A (pt) 2007-07-31
BRPI0508461B1 BRPI0508461B1 (pt) 2018-05-15
BRPI0508461B8 true BRPI0508461B8 (pt) 2021-05-25

Family

ID=34961010

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018003623A BR122018003623B8 (pt) 2004-03-05 2005-02-25 diaminopirimidinas, seus usos, e composição farmacêutica
BRPI0508461A BRPI0508461B8 (pt) 2004-03-05 2005-02-25 diaminopirimidinas, seus usos, e composição farmacêutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122018003623A BR122018003623B8 (pt) 2004-03-05 2005-02-25 diaminopirimidinas, seus usos, e composição farmacêutica

Country Status (28)

Country Link
US (10) US7858632B2 (pt)
EP (2) EP1725540B1 (pt)
JP (4) JP4717876B2 (pt)
KR (1) KR100822530B1 (pt)
CN (1) CN1930135B (pt)
AR (1) AR047992A1 (pt)
AU (1) AU2005229331B2 (pt)
BR (2) BR122018003623B8 (pt)
CA (1) CA2557372C (pt)
CY (1) CY1113450T1 (pt)
DK (1) DK1725540T5 (pt)
ES (2) ES2548022T3 (pt)
FI (1) FIC20240007I1 (pt)
HK (1) HK1101074A1 (pt)
HR (1) HRP20120901T1 (pt)
HU (1) HUS2400005I1 (pt)
IL (2) IL177438A (pt)
MY (1) MY145465A (pt)
NL (1) NL301261I2 (pt)
NO (3) NO339497B1 (pt)
NZ (1) NZ549069A (pt)
PL (1) PL1725540T3 (pt)
PT (1) PT1725540E (pt)
RU (1) RU2422441C2 (pt)
SI (1) SI1725540T1 (pt)
TW (1) TWI313604B (pt)
WO (1) WO2005095359A1 (pt)
ZA (1) ZA200606880B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1725540T3 (pl) * 2004-03-05 2013-02-28 Hoffmann La Roche Diaminopirymidyny jako antagoniści p2x3 i p2x2/3
US8592419B2 (en) * 2004-10-29 2013-11-26 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
ES2374750T3 (es) * 2005-09-01 2012-02-21 F. Hoffmann-La Roche Ag Proceso de síntesis de ariloxidiaminopirimidinas.
JP4850913B2 (ja) * 2005-09-01 2012-01-11 エフ.ホフマン−ラ ロシュ アーゲー P2x3及びp2x2/3調節因子としてのジアミノピリジン
KR101012926B1 (ko) * 2005-09-01 2011-02-09 에프. 호프만-라 로슈 아게 P2x3 및 p2x2/3 조정자로서의 다이아미노피리미딘
ES2601178T3 (es) * 2005-09-01 2017-02-14 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P3X2/3
WO2007025899A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
EP1770089A1 (en) * 2005-10-03 2007-04-04 Institut Pasteur Pyranodibenzofuran derivatives with antifungal and antibacterial activity
EP2343281B1 (en) * 2006-10-04 2014-03-05 F. Hoffmann-La Roche AG Process for synthesis of phenoxy diaminopyrimidine derivatives
KR101165936B1 (ko) * 2006-11-09 2012-07-19 에프. 호프만-라 로슈 아게 티아졸 및 옥사졸-치환된 아릴아마이드
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
WO2008104472A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof
US8101644B2 (en) 2007-03-30 2012-01-24 Shionogi & Co., Ltd. Pyrrolinone derivative and pharmaceutical composition comprising the same
AU2008326309C1 (en) * 2007-11-21 2015-03-12 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
WO2010035727A1 (ja) * 2008-09-25 2010-04-01 塩野義製薬株式会社 新規ピロリノン誘導体およびそれを含有する医薬組成物
EP2348839B1 (en) 2008-11-06 2017-04-05 MUSC Foundation For Research Development Lysosomotropic inhibitors of acid ceramidase
EP2367794B1 (en) 2008-11-24 2013-01-09 Basf Se Curable composition comprising a thermolatent base
EP2384118A4 (en) * 2008-12-30 2012-01-11 Musc Found For Res Dev SPHINGOGUANIDINE AND ITS USE AS AN INHIBITOR OF SPHINGOSINKINASE
CA2752269C (en) 2009-02-13 2016-08-30 Hiroyuki Kai Novel triazine derivative and pharmaceutical composition comprising the same
EA201290062A1 (ru) * 2009-08-17 2013-09-30 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений
CN103140221A (zh) * 2010-08-10 2013-06-05 盐野义制药株式会社 新型杂环衍生物和含有其的药物组合物
MX346367B (es) 2010-08-10 2017-03-16 Shionogi & Co Ltd * Derivado de triazina y composicion farmaceutica que tiene actividad analgesica que comprende el mismo.
US9550763B2 (en) 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
EP3865134A1 (en) 2013-08-23 2021-08-18 Afferent Pharmaceuticals Inc. Methods of using diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases
WO2015175707A1 (en) 2014-05-13 2015-11-19 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same
EP3981406A1 (en) 2014-07-03 2022-04-13 Afferent Pharmaceuticals Inc. Methods and compositions for treating diseases and conditions
PT3192512T (pt) 2014-09-09 2019-10-29 Cytokinetics Inc Nova composição farmacêutica para prevenção e/ou tratamento de incontinência urinária
RU2585727C1 (ru) * 2014-12-12 2016-06-10 Наталья Борисовна Гусева Способ лечения детей с гиперактивным мочевым пузырем
PT3355889T (pt) 2015-09-29 2023-04-26 Afferent Pharmaceuticals Inc Moduladores de recetores de diaminopirimidina p2x3 e p2x2/3 para utilização no tratamento da tosse
CA3016773A1 (en) 2016-03-14 2017-09-21 Ronald Charles Hawley Pyrimidines and variants thereof, and uses therefor
MX2018011622A (es) * 2016-03-25 2019-03-28 Afferent Pharmaceuticals Inc Pirimidinas y sus variantes, y usos de las mismas.
CN106083653A (zh) * 2016-06-06 2016-11-09 江苏天和制药有限公司 奥美普林中间体肉桂腈的合成方法
EP3558315A4 (en) * 2016-12-20 2020-07-15 Afferent Pharmaceuticals Inc. CRYSTALLINE SALTS AND POLYMORPH OF A P2X3 ANTAGONIST
EP3712144B1 (en) * 2017-11-01 2024-02-14 Beijing Tide Pharmaceutical Co., Ltd. P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
CN112423756A (zh) * 2018-04-23 2021-02-26 默沙东公司 用于合成苯氧基二氨基嘧啶化合物的新方法
CN112262121A (zh) * 2018-06-15 2021-01-22 法尔玛赞公司 用于制备他喷他多的新方法
AU2020265327A1 (en) * 2019-04-30 2021-12-16 Beijing Tide Pharmaceutical Co., Ltd. Method for treating cough by using diaminopyrimidine compound
CN113993858A (zh) * 2019-04-30 2022-01-28 北京泰德制药股份有限公司 二氨基嘧啶类化合物或其水合物的固体形式及其制备方法和用途
WO2020239951A1 (en) * 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
WO2020244607A1 (zh) * 2019-06-06 2020-12-10 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途
CN110551147B (zh) * 2019-09-29 2021-11-26 蚌埠产品质量监督检验研究院 一种3-环丙基苯硼酸的合成方法
TW202215157A (zh) * 2020-06-01 2022-04-16 日商住友化學股份有限公司 化合物、樹脂、抗蝕劑組成物及抗蝕劑圖案的製造方法
WO2022033567A1 (zh) 2020-08-13 2022-02-17 上海拓界生物医药科技有限公司 苯并咪唑类衍生物、其制备方法及医药用途
EP4214195A1 (en) 2020-09-17 2023-07-26 Teva Pharmaceuticals International GmbH Solid state forms of gefapixant and process for preparation thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2658897A (en) 1951-06-27 1953-11-10 Burroughs Wellcome Co 2, 4-diamino-5-benzyl pyrimidines
US2657206A (en) * 1951-07-30 1953-10-27 Burroughs Wellcome Co 2, 4-diamino-5-aryloxy-pyrimidines
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method
US2909522A (en) 1957-02-21 1959-10-20 Burroughs Wellcome Co Trialkoxybenzylpyrimidines and method
US4052553A (en) * 1969-03-06 1977-10-04 Burroughs Wellcome Co. 5-benzyl pyrimidines intermediates therefore, and method
US3850927A (en) * 1969-03-06 1974-11-26 Burroughs Wellcome Co 5-benzyl pyrimidines intermediates therefore,and method
GB1261455A (en) * 1969-03-06 1972-01-26 Burroughs Wellcome Co Improvements in or relating to substituted acrylonitriles
US3878252A (en) * 1970-09-24 1975-04-15 Burroughs Wellcome Co Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide
US3855265A (en) * 1969-03-06 1974-12-17 Burroughs Wellcome Co 5-benzyl pyrimidines intermediates therefore, and method
US3991050A (en) * 1969-03-06 1976-11-09 Burroughs Wellcome Co. Preparation of β-Amino-α-benzylacrylonitriles
US3849470A (en) * 1969-03-06 1974-11-19 Burroughs Wellcome Co 5-benzyl pyrimidines intermediates therefore,and method
US3852276A (en) * 1969-03-06 1974-12-03 Burroughs Wellcome Co 5-benzyl pyrimidines intermediate therefore, and method
BR6915082D0 (pt) * 1969-05-16 1973-03-08 Wellcome Found Processo de preparacao de benzil-pirimidinas
CH513181A (de) * 1969-06-12 1971-09-30 Hoffmann La Roche Verfahren zur Herstellung von N-Oxyden von Benzylpyrimidinen
US4143227A (en) * 1973-02-26 1979-03-06 Hoffmann-La Roche Inc. Process for substituted 5-benzyl-2,4-diamino-pyrimidines
US4255574A (en) * 1973-02-26 1981-03-10 Hoffmann-La Roche Inc. Process for preparing 2,4-diamino-pyrimidines
US3931181A (en) * 1973-07-27 1976-01-06 Hoffmann-La Roche Inc. 2,4-Diamino-5-benzylpyrimidines
US4515948A (en) * 1973-09-12 1985-05-07 Hoffmann-La Roche Inc. 2,4-Diamino-5-(4-amino and 4-dimethylamino-3,5-dimethoxy benzyl)pyrimidines
CH591457A5 (pt) * 1973-11-08 1977-09-15 Hoffmann La Roche
US3940393A (en) * 1974-06-21 1976-02-24 American Home Products Corporation Synthesis of 2,6-diaminopyrimidines
US4039543A (en) * 1974-12-24 1977-08-02 Hoffmann-La Roche Inc. Benzylpyrimidines
US4033962A (en) * 1975-06-26 1977-07-05 Hoffman-La Roche Inc. 2,4-Diamino-pyrimidine derivatives and processes
GB1582245A (en) * 1976-06-09 1981-01-07 Wellcome Found Benzyl cyanoacetal derivatives and their conversion to pyrimidine derivatives
US4115650A (en) * 1976-11-17 1978-09-19 Hoffmann-La Roche Inc. Process for preparing 2,4-diamino-5-(substituted benzyl)-pyrimidines
US4075209A (en) * 1977-02-07 1978-02-21 Hoffmann-La Roche, Inc. Process for preparing substituted 2,4-diaminopyrimidines and isoxazole intermediate
FR2397407A2 (fr) * 1977-07-11 1979-02-09 Dick Pierre Derives de 2,4-diamino pyrimidines et leur mise en solution en association avec des sulfamides
US4258045A (en) * 1979-11-30 1981-03-24 Merck & Co., Inc. Inhibitor of dihydrofolate reductase
DE3045720A1 (de) * 1980-12-04 1982-07-08 Basf Ag, 6700 Ludwigshafen N-pyrimidinyl-carbaminsaeureester, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
FR2502152A1 (fr) * 1981-03-20 1982-09-24 Panmedica Laboratoires Nouveaux derives solubles n2 substitues de la diamino-2,4-benzyl-5-pyrimidines, leur procede de preparation et medicaments les contenant
IT1138146B (it) * 1981-08-11 1986-09-17 Proter Spa Processo per la produzione della 2,4-diammino-(3,5-dimetossi-4-metos sietossi-benzil)-pirimidina
GB2116962A (en) * 1982-03-18 1983-10-05 Ciba Geigy Ag Nitriles; pyrimidines
US4590271A (en) * 1982-05-01 1986-05-20 Burroughs Wellcome Co. 2,4-diamino-5-(substituted)pyrimidines, useful as antimicrobials
US4587341A (en) * 1982-05-07 1986-05-06 Burroughs Wellcome Co. 2,4-diamino-5-(1,2,3,4-tetrahydro-(substituted or unsubstituted)-6-quinolylmethyl)pyrimidines, useful as antimicrobials
US4515574A (en) * 1983-02-16 1985-05-07 The Zeller Corporation Universal joint seal with multiple lips
DE3603577A1 (de) * 1986-02-06 1987-08-13 Joachim K Prof Dr Seydel Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit
FR2595697B1 (fr) 1986-03-13 1988-07-08 Rousselot Cie Derives de benzyl-pyrimidine, leur procede de preparation ainsi que les compositions en contenant
HU199683B (en) * 1987-07-22 1990-03-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions analgesic, antiphlogistic, antipyretic, antianginic and/or antioxidative activity
US4996198A (en) * 1988-07-11 1991-02-26 Hoffmann-La Roche Inc. Anticoccidial composition
US5240640A (en) * 1990-06-04 1993-08-31 Coulter Corporation In situ use of gelatin or an aminodextran in the preparation of uniform ferrite particles
US5258373A (en) * 1991-07-17 1993-11-02 Hoffmann-La Roche Inc. Anticoccidial compositions
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
WO1996016963A1 (de) 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamide und deren verwendung als heilmittel
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
US6583148B1 (en) * 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6211185B1 (en) * 1999-05-05 2001-04-03 Veterinary Pharmacy Corporation Concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution, and a suspending agent
AU775194B2 (en) 1999-09-03 2004-07-22 Actelion Pharmaceuticals Ltd Bis-sulfonamides
BRPI0014271B1 (pt) 1999-09-24 2021-06-22 Janssen Pharmaceutica N.V. Partícula consistindo em uma dispersão de sólidos, uso da dita partícula, dispersão de sólidos, forma de dosagem farmacêutica, bem como processos de preparação de dita partícula, dispersão e forma de dosagem
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
US6515198B2 (en) * 2000-02-15 2003-02-04 Syntex (U.S.A.) Llc Use of purinergic receptor modulators and related reagents
WO2001081335A1 (en) 2000-04-20 2001-11-01 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
WO2001081338A1 (en) 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
BR0114082A (pt) 2000-09-25 2003-07-22 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
US7094781B2 (en) 2000-12-18 2006-08-22 Actelion Pharmaceuticals Ltd. Sulfamides and their use as endothelin receptor antagonists
US6423720B1 (en) * 2001-02-01 2002-07-23 Duquesne University Of The Holy Ghost Pyrimidine compounds and methods for making and using the same
WO2002083650A1 (en) 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
MXPA03010586A (es) * 2001-05-18 2004-04-02 Abbott Lab N-[(1s)-1,2,3,4-tertrahidro-1-naftalenil benzamidas trisubtituidas, las cuales inhiben receptores que contienen p2x2/3.
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PL1725540T3 (pl) * 2004-03-05 2013-02-28 Hoffmann La Roche Diaminopirymidyny jako antagoniści p2x3 i p2x2/3
JP4850913B2 (ja) * 2005-09-01 2012-01-11 エフ.ホフマン−ラ ロシュ アーゲー P2x3及びp2x2/3調節因子としてのジアミノピリジン
KR101012926B1 (ko) * 2005-09-01 2011-02-09 에프. 호프만-라 로슈 아게 P2x3 및 p2x2/3 조정자로서의 다이아미노피리미딘
ES2601178T3 (es) * 2005-09-01 2017-02-14 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P3X2/3
WO2008104472A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof

Also Published As

Publication number Publication date
US9556127B2 (en) 2017-01-31
JP4717876B2 (ja) 2011-07-06
TWI313604B (en) 2009-08-21
CY1113450T1 (el) 2016-06-22
EP1725540B1 (en) 2012-09-12
WO2005095359A1 (en) 2005-10-13
US20170096404A1 (en) 2017-04-06
DK1725540T3 (da) 2012-10-01
US7858632B2 (en) 2010-12-28
NO20161635A1 (no) 2016-10-12
JP2014193906A (ja) 2014-10-09
EP2343282A1 (en) 2011-07-13
CA2557372C (en) 2013-01-08
AU2005229331A1 (en) 2005-10-13
JP2007526268A (ja) 2007-09-13
US20140357629A1 (en) 2014-12-04
BR122018003623B1 (pt) 2018-10-09
BRPI0508461A (pt) 2007-07-31
US8846705B2 (en) 2014-09-30
US20190270713A1 (en) 2019-09-05
JP5576314B2 (ja) 2014-08-20
HK1101074A1 (en) 2007-10-05
ZA200606880B (en) 2008-04-30
NO20064065L (no) 2006-11-28
CN1930135A (zh) 2007-03-14
IL217453A0 (en) 2012-02-29
AR047992A1 (es) 2006-03-15
US20180141919A1 (en) 2018-05-24
CN1930135B (zh) 2011-12-28
IL217453A (en) 2014-12-31
IL177438A0 (en) 2006-12-10
RU2006135203A (ru) 2008-04-10
US20200115347A1 (en) 2020-04-16
HRP20120901T1 (hr) 2012-12-31
JP5886898B2 (ja) 2016-03-16
BRPI0508461B1 (pt) 2018-05-15
ES2391636T3 (es) 2012-11-28
US20110077242A1 (en) 2011-03-31
US20210009531A1 (en) 2021-01-14
PT1725540E (pt) 2012-11-29
CA2557372A1 (en) 2005-10-13
US20230100975A1 (en) 2023-03-30
KR100822530B1 (ko) 2008-04-16
ES2548022T3 (es) 2015-10-13
PL1725540T3 (pl) 2013-02-28
JP5465700B2 (ja) 2014-04-09
EP2343282B1 (en) 2015-07-22
FIC20240007I1 (fi) 2024-03-13
NO20150504L (no) 2006-11-28
DK1725540T5 (da) 2012-10-22
TW200539885A (en) 2005-12-16
NL301261I2 (nl) 2024-03-25
JP2011252004A (ja) 2011-12-15
US20050209260A1 (en) 2005-09-22
NZ549069A (en) 2010-09-30
EP1725540A1 (en) 2006-11-29
BR122018003623B8 (pt) 2021-07-27
NO339497B1 (no) 2016-12-19
RU2422441C2 (ru) 2011-06-27
IL177438A (en) 2012-10-31
HUS2400005I1 (hu) 2024-04-28
AU2005229331B2 (en) 2011-10-13
SI1725540T1 (sl) 2012-12-31
JP2011126899A (ja) 2011-06-30
MY145465A (en) 2012-02-15
NO343755B1 (no) 2019-05-27
US20190016688A1 (en) 2019-01-17
KR20060117366A (ko) 2006-11-16

Similar Documents

Publication Publication Date Title
BRPI0508461B8 (pt) diaminopirimidinas, seus usos, e composição farmacêutica
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
MA29432B1 (fr) Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BRPI0821266B8 (pt) Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR122019017036B8 (pt) compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica
DK2152709T3 (da) Morphinanforbindelser
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
TW200740773A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
AR066701A1 (es) 3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapia
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
DE602007012313D1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112018073410A2 (pt) combinação de antagonistas, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BRPI0606750A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e,composição farmacêutica
BR112014011262A8 (pt) compostos substituídos de carboxamida à base de pirazolila substituída e derivados de ureia, seus usos, e composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/02/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF